[Safety and the short-term efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with lymphoma].
作者信息
An L C, Liu Y H, Wang J Y, Ma J J, Xu J Q, Li K M, Wei R X, Sui J R, Feng X Y, Liu X Q, Chen L M, Chu X X
机构信息
Department of Hematology, Yantai Yuhuangding Hospital, Yantai 264000, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2022 Jan 14;43(1):63-65. doi: 10.3760/cma.j.issn.0253-2727.2022.01.012.
Abstract
摘要
相似文献
1
[Safety and the short-term efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with lymphoma].[苯达莫司汀在淋巴瘤患者自体干细胞移植预处理方案中的安全性及短期疗效]
Zhonghua Xue Ye Xue Za Zhi. 2022 Jan 14;43(1):63-65. doi: 10.3760/cma.j.issn.0253-2727.2022.01.012.
2
High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity.高剂量苯达莫司汀联合 EAM 方案继以自体干细胞解救治疗可使淋巴瘤患者获得长期缓解，且无肾毒性。
Eur J Haematol. 2018 Sep;101(3):326-331. doi: 10.1111/ejh.13102. Epub 2018 Aug 3.
3
Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for autologous hematopoietic stem cell transplantation.一项单中心回顾性研究，评估苯达莫司汀、依托泊苷、阿糖胞苷、美法仑（BeEAM）作为自体造血干细胞移植预处理方案的疗效和安全性。
Leuk Lymphoma. 2023 Jul-Aug;64(7):1234-1242. doi: 10.1080/10428194.2023.2203790. Epub 2023 May 8.
4
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.BeEAM（苯达莫司汀、依托泊苷、阿糖胞苷、美法仑）在自体造血干细胞移植前对耐药/复发的淋巴瘤患者安全且有效。
Blood. 2011 Sep 22;118(12):3419-25. doi: 10.1182/blood-2011-04-351924. Epub 2011 Aug 3.
5
Phase II study of safety and efficacy of BEB (bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma.非霍奇金淋巴瘤患者自体干细胞移植中 BEB（苯达莫司汀、依托泊苷和白消安）预处理方案的安全性和疗效的 II 期研究。
Ann Hematol. 2020 Apr;99(4):819-828. doi: 10.1007/s00277-020-03942-6. Epub 2020 Feb 5.
6
High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning Before Autologous Transplantation for Patients With Multiple Myeloma.高剂量苯达莫司汀、依托泊苷、阿糖胞苷和马法兰（BeEAM）预处理后自体移植治疗多发性骨髓瘤患者。
Transplant Cell Ther. 2022 Aug;28(8):486.e1-486.e7. doi: 10.1016/j.jtct.2022.05.022. Epub 2022 May 20.
7
BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres.在滤泡性淋巴瘤患者对化疗敏感的复发时，自体干细胞移植前使用BeEAM（苯达莫司汀、依托泊苷、阿糖胞苷、美法仑）：淋巴瘤研究协会中心的一项前瞻性多中心II期研究
Br J Haematol. 2021 Feb;192(3):e94-e98. doi: 10.1111/bjh.17279. Epub 2021 Jan 9.
8
Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers.苯达莫司汀预处理后自体造血干细胞移植（ASCT）：LYmphoma Study Association（LYSA）中心 474 例患者的法国多中心研究结果。
Am J Hematol. 2018 Jun;93(6):729-735. doi: 10.1002/ajh.25077. Epub 2018 Mar 14.
9
CBeV (cyclophosphamide, bendamustine and etoposide) pre-autotransplant conditioning in persons with lymphoma.淋巴瘤患者的环磷酰胺、苯达莫司汀和依托泊苷（CBeV）自体移植前预处理
Bone Marrow Transplant. 2020 Jan;55(1):265-267. doi: 10.1038/s41409-019-0528-y. Epub 2019 Apr 23.
10
Conditioning regimen with BCNU, etoposide, cytarabine and melphalan plus amifostine for outpatient autologous stem cell transplant: feasibility and outcome in 97 patients with lymphoma.采用卡莫司汀、依托泊苷、阿糖胞苷、美法仑加氨磷汀进行预处理方案用于门诊自体干细胞移植：97例淋巴瘤患者的可行性及结果
Leuk Lymphoma. 2014 Jul;55(7):1657-60. doi: 10.3109/10428194.2013.842989. Epub 2013 Nov 1.
本文引用的文献
1
Phase II study of safety and efficacy of BEB (bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma.非霍奇金淋巴瘤患者自体干细胞移植中 BEB（苯达莫司汀、依托泊苷和白消安）预处理方案的安全性和疗效的 II 期研究。
Ann Hematol. 2020 Apr;99(4):819-828. doi: 10.1007/s00277-020-03942-6. Epub 2020 Feb 5.
2
Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group.苯达莫司汀作为侵袭性淋巴瘤患者自体干细胞移植预处理方案的一部分：GELTAMO 研究组的一项 2 期研究。
Br J Haematol. 2019 Mar;184(5):797-807. doi: 10.1111/bjh.15713. Epub 2018 Dec 12.
3
Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers.苯达莫司汀预处理后自体造血干细胞移植（ASCT）：LYmphoma Study Association（LYSA）中心 474 例患者的法国多中心研究结果。
Am J Hematol. 2018 Jun;93(6):729-735. doi: 10.1002/ajh.25077. Epub 2018 Mar 14.
4
Hodgkin lymphoma: A review and update on recent progress.霍奇金淋巴瘤：近期进展的综述和更新。
CA Cancer J Clin. 2018 Mar;68(2):116-132. doi: 10.3322/caac.21438. Epub 2017 Dec 1.
5
Non-Hodgkin lymphoma.非霍奇金淋巴瘤。
Lancet. 2017 Jul 15;390(10091):298-310. doi: 10.1016/S0140-6736(16)32407-2. Epub 2017 Jan 31.
6
Comparison of CBV, BEAM and BEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non-Hodgkin lymphoma: Efficacy and toxicity.非霍奇金淋巴瘤中CBV、BEAM和BEAC大剂量化疗后自体造血干细胞移植的比较：疗效与毒性
Asia Pac J Clin Oncol. 2017 Oct;13(5):e423-e429. doi: 10.1111/ajco.12610. Epub 2017 Jan 19.
7
Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning.用于治疗复发/难治性非霍奇金淋巴瘤和霍奇金淋巴瘤成人患者的自体干细胞移植前的新型方案：替代BEAM预处理方案。
Leuk Lymphoma. 2016 Nov;57(11):2499-509. doi: 10.1080/10428194.2016.1185785. Epub 2016 May 31.
8
The 2016 revision of the World Health Organization classification of lymphoid neoplasms.《世界卫生组织淋巴组织肿瘤分类（2016年修订版）》
Blood. 2016 May 19;127(20):2375-90. doi: 10.1182/blood-2016-01-643569. Epub 2016 Mar 15.
9
Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity.基于苯达莫司汀的预处理方案用于非霍奇金淋巴瘤自体移植：肾毒性风险增加
Bone Marrow Transplant. 2016 Feb;51(2):319-21. doi: 10.1038/bmt.2015.257. Epub 2015 Nov 2.
10
Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma.苯达莫司汀、依托泊苷、阿糖胞苷、美法仑及自体干细胞救援在难治性淋巴瘤中产生72%的3年无进展生存率。
Blood. 2014 Nov 6;124(19):3029-31. doi: 10.1182/blood-2014-08-596668.
Zotero 插件